ELEPHANTS RARELY GET CANCER

 A

A

Elephants rarely get cancer due to a unique genetic advantage—they have multiple copies of the tumor-suppressor gene TP53. Here’s a breakdown of why this matters:

1. The Role of TP53 Gene:

• TP53 is known as the "guardian of the genome." It helps detect and repair damaged DNA or triggers cell death (apoptosis) if the damage is irreparable.
• Humans have two copies of the TP53 gene (one from each parent), while elephants have around 40 copies. This means they are better equipped to prevent cancerous cell growth.

2. Enhanced DNA Repair and Cell Death:

• If cells in an elephant’s body become damaged, their extra TP53 genes quickly signal the cells to self-destruct. This prevents the formation of tumors.
• In humans, defective TP53 genes can lead to increased cancer risk (e.g., in Li-Fraumeni syndrome).

3. LIF6 – The “Zombie Gene”:

• Elephants also have a special "resurrected" gene called LIF6. This gene was once inactive in evolutionary history but became functional again.
• When DNA damage occurs, LIF6 triggers cell death, adding another layer of protection against cancer.

4. Body Size Paradox (Peto’s Paradox):

• Larger animals with more cells (like elephants) should statistically have a higher cancer risk. However, elephants defy this expectation due to their robust anti-cancer mechanisms.
• This paradox, known as Peto's Paradox, suggests that evolutionary adaptations in long-lived, large animals reduce cancer susceptibility.

5. Implications for Human Medicine:

• Researchers are studying elephant genetics to develop new cancer treatments for humans. Understanding how TP53 and LIF6 work could lead to improved therapies and preventive measures.

Would you like to know more about other animals with cancer resistance or how this research applies to human medicine?

A